Biotech Weakness but why Large Caps?…Updates
Update: 10:10a Tesaro (TSRO) Soars 15% to $38, short covering or bargain hunters? News item: expansion of Zejula Combo Trial in NSCLC ========= Biotech Weakness in Large Caps Mid-Caps Have Continued Strength The overall market recovered from an early sell-off but there was pronounced biotech...
Biotechs Surge in August Best in Years: New Highs Hit for 2018…Updates
9/4/18 Biotech Weakness -Profit Taking or Caution for September Swoon? 1 PM EDT FBT down 1.38%, IBB down 1.55%, XBI down 0.73% Biotech stocks were extremely weak as of mid-day trading. Large caps were unusually weak given that they should be less volatile: CELG down 3.55%, BIIB down 3.06%, ALXN...
IBB Hits 2018 High but FBT is Still the Leading ETF over 5 Years: CAR-T, RNAi …Updates
8/30/18 Weak Rally to another Round of Highs Curbed by more Tough Tariff Threats This week’s rally and uber bullish sentiment was slowed by Tough Talk about $200B in new tariffs next week. Other news from Trump on Google, Facebook and Amazon threatening antitrust action curbed buyers at...
Biotech Snapshot: Healthcare Sector Remains Strong-Updates
8/24/18 After Close: Rally Continues with 10/11 Sectors Higher XLV finishes at all time high at $91.89 FED’s Powell Defends Gradual Interest Rate Policy despite Trump pressure Oil Surges 15 to $68.57 on supply concerns with Iran sanctions Major indices hit 52 week highs: S&P 500,...
Vacation Week: Limited Postings…Updates 8/18 GILD XLV
Biotech Weekly Ending 8/18 …Five Day Performance The Biotech sector held on a turbulent geopolitical week favoring large caps. Amgen (AMGN) up 1.7%, Merck (MRK) up 3.6%, Regeneron (REGN) up 2.1%. Gilead Sciences (GILD) was off 6% on concerns it would lose market share of its HIV drug to...
